Compare Medpace Holdings Inc (MEDP) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs SanDisk — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while SanDisk trades at $1,581.3 (market cap $232.61B). The key difference: SanDisk is far larger — about 13.8× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 9,218,054). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and SanDisk for 8 Days on average.
| MEDP | SNDK | |
|---|---|---|
Market Cap | $16.82B | $232.61B |
Volume | 223,093 | 9,218,054 |
Sector | Health | Technology |
52-Week High | $630.19 | $2.34K |
52-Week Low | $393.42 | $116.91 |
Typical Hold Time | 14 Days | 8 Days |
Enterprise Value | $16.44B | $228.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SNDK trades at $1,581.82, down 6.54% amid recent volatility, yet maintains strong analyst support with 87.5% buy ratings and a $2,160 consensus price target. The stock shows exceptional profitability metrics including 71.47% gross margins and 91.64% ROE, though current earnings reflect a net loss of -$1.64B for 2025. Recent news highlights institutional positioning shifts and AI-driven memory demand dynamics affecting performance.
Outlook remains cautiously optimistic given projected 2026 revenue growth to $20.2B and net profit of $11.4B, but risks include memory cycle volatility and competitive pressures. Technical indicators suggest near-term bearish pressure with key support at $1,575, while fundamental strength in profitability metrics supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
